- Associated Press - Thursday, January 29, 2015

LITTLE ROCK, Ark. (AP) - A University of Arkansas for Medical Sciences startup company has received $14.5 million in federal grants to develop drug therapies aiming to help methamphetamine abusers break their addiction.

The company, InterveXion Therapeutics LLC, will develop therapies to reduce or prevent the euphoric rush that drug users crave by keeping methamphetamine in the bloodstream and out of the brain - where the drug exerts its most powerful effects.

The larger of the two grants - $9.55 million over three years- will support research to determine whether a methamphetamine vaccine may be safely advanced into a clinical trial with human participants.

The other grant of $5 million over three years will support production of the anti-methamphetamine monoclonal antibody that has been successfully tested in a first clinical study of healthy adults.

Sign up for Daily Newsletters

Manage Newsletters

Copyright © 2020 The Washington Times, LLC.

Please read our comment policy before commenting.


Click to Read More and View Comments

Click to Hide